Govee Goes Big On Design For New Smart Lamp Line-Up
Govee has taken the covers off of a trio of unique new smart lamps, with the Chinese brand's new floor lamp series comprised of three distinct models built to do more than just glow in a corner.
The Tree, Uplighter, and Torchiere Floor Lamps - which have just been revealed for the German market - aim to turn your walls and ceilings into mood-setting light shows.
Starting with the Tree Floor Lamp, and it's got a sculptural three-head design that looks more like modern decor than traditional lighting.
Govee's new Tree Floor Lamp
Each lamp head can swivel 350° side-to-side and tilt 90° up or down, with beam angles that go from narrow spotlighting to wide ambient wash. That means it should be good for both highlighting a bookshelf as it is mood-lighting a Netflix night.
It packs Govee's RGBWW tech, with LuminBlend smooth transitions, 16 million colors, and brightness up to 1500 lumens. It's tunable from 2700K to 6500K and comes with 64 scene presets, app control, voice support, and full Matter compatibility.
The Uplighter is a triple-threat, with a ceiling-facing ripple light at the top, a decorative RGBIC strip in the middle, and a lower lamp that beams out 1000 lumens for actual task lighting.
Govee's new Uplighter Floor Lamp
It's looks to be the most 'routine-ready' of the bunch, with circadian lighting and automation features built in.
The Torchiere keeps things a little more relaxed, but still has plenty of smarts. It focuses on ambient glow with triple-zone RGB control, a soft output that's easy on the eyes, and a built-in music sync mode for your chill-out playlists or party nights.
Govee's new Torchiere Floor Lamp
As with the rest of Govee's ecosystem, all three lamps play nicely with Alexa, Google Assistant, and they are all Matter compatible.
Everything's manageable via the, much improved, Govee app, where you'll get all the usual features such as timers, DIY scenes, and routines.
They're on sale in Germany now, I'd expect a US launch to follow soon.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Alvotech (ALVO) Announces a Commercialization Agreement With Advanz Pharma
Alvotech (NASDAQ:ALVO) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, Alvotech (NASDAQ:ALVO) and Advanz Pharma announced a commercialization agreement to distribute and supply AVT10, a biosimilar candidate to Cimzia, in Europe. A scientist in a laboratory working on drug research. The agreement is expected to support Alvotech's (NASDAQ:ALVO) strategic position in the biosimilar market while allowing increased access to high-quality biologics in Europe. This could potentially affect the market share of the current treatments in the chronic rheumatic diseases sector. Alvotech (NASDAQ:ALVO) is a biotechnology company that develops and manufactures biosimilar medicines. Headquartered in Luxembourg, the company operates in the following geographical segments: Europe, North America, Asia, and Other. While we acknowledge the potential of ALVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
HubSpot Expands CRM Expertise Through Partnership with MatrixPoint
HubSpot Inc. (NYSE:HUBS) is one of the best NYSE stocks to buy for long term investment. As May was coming to an end, MatrixPoint announced its collaboration with HubSpot by joining its Solutions Partner Program. The partnership will enhance customer engagement and expand CRM/Customer Relationship Management expertise. The HubSpot Solutions Partner Program is a global network of experts providing services in marketing, sales, customer service, web design, CRM, and IT. This ecosystem emphasizes a customer-first approach for growth, which enables its members, like MatrixPoint, to offer a wider range of sophisticated solutions. A team of software developers gathered around a monitor discussing a new CRM platform. MatrixPoint is a results-driven media consultancy that empowers businesses to achieve more through marketing transformation and strategic growth. It will specifically expand its CRM practice through this partnership to help clients better use their customer data for more intelligent and personalized engagement. HubSpot Inc. (NYSE:HUBS) provides a cloud-based CRM platform for businesses in the Americas, Europe, and the Asia Pacific. While we acknowledge the potential of HUBS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
